Stoke Therapeutics, Inc. (STOK) Operating cash flow 2018–2025
Stoke Therapeutics, Inc. (STOK) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
$45.6MFY2025 · since FY2018: -$11.0M → $45.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $45.6M | +152.5% |
| FY2024 | -$86.9M | -7.1% |
| FY2023 | -$81.1M | -154.4% |
| FY2022 | -$31.9M | +52.4% |
| FY2021 | -$66.9M | -58.5% |
| FY2020 | -$42.2M | -36.0% |
| FY2019 | -$31.1M | -183.2% |
| FY2018 | -$11.0M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More STOK financial trends
STOK RevenueSTOK Net incomeSTOK Net marginSTOK Gross profitSTOK Gross marginSTOK Operating incomeSTOK Operating marginSTOK Free cash flowSTOK Capital expendituresSTOK Return on equitySTOK Stock buybacksSTOK Dividends paidSTOK Total assetsSTOK Total liabilitiesSTOK Shareholders’ equitySTOK overview →